Other off-label indications under Health Canada included Myasthenia Gravis, Multiple Sclerosis, repeated Implantation Failure, Antiphospholipid syndrome, Rheumatoid arthritis, Pemphigoid Gestationis, Anti-Ro antibodies, HDFN, Antibody-mediated rejection (renal transplant), Chronic Villitis, Small fiber polyneuropathy, Idiopathic Angioedema, and Autoimmune Necrotizing Myositis. This evidence concerns the gene CALR and antiphospholipid syndrome.